These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Ribozymes: a new frontier in anti-HIV strategy. Sarver N Antisense Res Dev; 1991; 1(4):373-8. PubMed ID: 1821659 [TBL] [Abstract][Full Text] [Related]
9. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Taylor NR; Kaplan BE; Swiderski P; Li H; Rossi JJ Nucleic Acids Res; 1992 Sep; 20(17):4559-65. PubMed ID: 1408757 [TBL] [Abstract][Full Text] [Related]
18. Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes. Prislei S; Buonomo SB; Michienzi A; Bozzoni I RNA; 1997 Jun; 3(6):677-87. PubMed ID: 9174101 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Nosrati M; Li S; Bagheri S; Ginzinger D; Blackburn EH; Debs RJ; Kashani-Sabet M Clin Cancer Res; 2004 Aug; 10(15):4983-90. PubMed ID: 15297398 [TBL] [Abstract][Full Text] [Related]
20. Ribozyme-mediated decrease in mumps virus nucleocapsid mRNA level and progeny in infected vero cells. Albuquerque-Silva J; Milican F; Bollen A; Houard S Antisense Nucleic Acid Drug Dev; 1999 Jun; 9(3):279-88. PubMed ID: 10435753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]